View Clinical Trial (Medical Research Study)
Nebivolol and the Endothelin (ET)-1 System
| City: |
|
Boulder |
| State: |
|
Colorado |
| Zip Code: |
|
80309 |
| Conditions: |
|
Prehypertension - Hypertension |
| Purpose: |
|
The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor tone
in adult humans with elevated blood pressure to a greater extent than either metoprolol or
placebo.
|
| Study Summary: |
|
1. The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor
tone in adult humans with elevated blood pressure to a greater extent than either
metoprolol or placebo.
2. The investigators further hypothesize that reducing ET-1 vasoconstrictor activity
contributes to the improvement in endothelial vasodilator function associated with
nebivolol.
|
| Criteria: |
|
Inclusion Criteria:
- Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.
- Subjects will be prehypertensive/hypertensive defined as resting systolic blood
pressure >130 mmHg and < 160 mm Hg and/or diastolic blood pressure >80 mmHg and < 100
mm Hg.
- All of the women in the study will be postmenopausal (at least 1 year from last
menstrual cycle) and not receiving hormone replacement therapy (HRT) currently or in
the preceding 3-year period.
- Lastly, candidates will be sedentary as determined from the Stanford Physical
Activity Questionnaire (<35 kcal/wk) and will not have engaged in any program of
regular physical activity for at least 1 year prior to the study.
Exclusion Criteria:
- Candidates who smoke (currently or in the past 7 years), report more than low-risk
alcohol consumption as defined as no more than 14 standard drinks/wk and no more than
4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for
women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1½ ounces
of 80-proof distilled spirits)
- Potential candidates who are taking cardiovascular-acting (i.e. statins, blood
pressure medication an aspirin) medications will not be eligible.
- Fasting plasma glucose >126 mg/dL.
- Potential candidates with a resting heart rate of < 50 beats/minute will be excluded.
- Use of hormone replacement therapy.
- In hypertensive subjects, a seated systolic blood pressure greater than 160 mmHg or a
seated diastolic blood pressure greater than 100 mmHg.
|
| NCT ID: |
|
NCT01395329 |
| Primary Contact: |
|
Principal Investigator
Christopher A DeSouza, Ph.D.
University of Colorado at Boulder
Jared J Greiner, M.S.
Phone: 303-735-4955
Email: jared.greiner@colorado.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Boulder, Colorado 80309
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|